Zero Carbon Ammonia? What happened last night?
Published 28-APR-2021 10:02 A.M.
3 minute read
Minbos Resources (ASX:MNB) is developing a large phosphate resource in Angola that has the potential to dramatically transform the country’s food security and crop yields.
...and now Zero Carbon Ammonia?
Last night MNB delivered its quarterly update with no real surprises... except for one buried towards the end that we found pretty interesting...
Having a casual read of the quarterly was a nice stroll down memory lane of what MNB achieved over the last few months - execution of license with Angolan Government.. $7.3M now in the bank... fully funded to DFS on its US$159-260M (After Tax NPV) phosphate project that will cost between $22M to $28M to develop...
All this is already known information until we get to the second last page and see this, which is new:
Interesting... here is a summary we found of what Green Ammonia is (thanks Argus) - and a handy picture from their article:
We are watching with interest with MNB potentially jumping on the “ZERO CARBON” bandwagon after the success of Vulcan’s Zero Carbon Lithium (20c to now $8.20) and Province’s Zero Carbon Green Hydrogen (1.3c to now 21c).
Obviously it’s very early days and we don’t know what MNB is cooking up here but it certainly made us do a double take when reading the quarterly - we are invested in MNB for the original phosphate project but see the potential Zero Carbon Ammonia as a bonus.
As always we will keep providing our comments when more is revealed by MNB.
Here is all our past commentary on MNB
In other news... what’s happening with CPH?
As mentioned yesterday, we stayed up last night to watch Creso Pharma (ASX:CPH)’s “bigger brother” MindMed list on the NASDAQ.
MindMed and CPH are both in the psychedelics space, and share some of the same team - Dr Miri Wernli founded CPH and remains a significant CPH shareholder - she is now an Exec President and MindMed board member. Bruce Linton is a strategic advisor to CPH, and is on the board of MindMed.
MindMed is capped at over $2BN AUD right now, almost 10x bigger than CPH...
We think MindMed’s bigger valuation might be due to its significant North American presence and now multiple stock listings over there.
American investors' have a voracious appetite for psychedelic and marijuana investments that helps MindMed’s cause (and hopefully CPH’s when it lists there soon).
MindMed’s day one on NASDAQ saw it pop on open at $US 5.65 and close 30% lower at $US 4.02, back up to $US 4.35 in aftermarket trade.
MindMed is still up over 100% in the last 3 days - and up 1,000% over the last eight months.
MindMed has huge online support so we think it will continue to perform well, and we will bring you a further update on its NASDAQ performance over the coming weeks.
We are hoping that CPH and its similarly interesting story of cannabis and psychedelics will resonate well with the huge investor pool in the USA who are following MindMed.
We continue to be in awe at just how big the pool of investors is in the USA and Canada is - it’s always interesting when companies can get a following over there (we all saw what happened with 88E).
Here are a couple of links if you want to follow MindMeds trailblazing journey into the US Psychedelics investor community:
- Watch the MindMed founder interviewed on CNN yesterday.
- Check out this article on Yahoo News: MindMed to become second psychedelic drug developer to go public in the U.S..
This video also outlines the MindMed opportunity from the Psychedelic Investor Youtube channel.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.